Cochrane Collaborative Review Group on Peripheral Vascular Diseases: Review abstracts  by unknown
COCHRANE REVIEWS
Cochrane Collaborative Review Group on Peripheral
Vascular Diseases: Review Abstracts
Introduction
The following abstract is part of an ongoing series of
articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases, which
is part of the Cochrane Collaboration. The reviews are
published in full on `The Cochrane Library', a quar-
terly electronic journal available on CD-ROM and via
the Internet. The electronic format allows Cochrane
reviews to accommodate new data as they become avai-
lable, making the library a consistently up-to-date
source of information over time.
Certain abstracts appearing on the Cochrane
Library may be presented in a simpler, less scientific
format than the abstract presented here to permit
greater accessibility to the public. However, the sub-
stance of both versions is the same. Cochrane reviews
are now indexed on MEDLINE.
If you are interested in writing a Cochrane review or
contributing to the activities of the Cochrane Periph-
eral Vascular Diseases Group please contact:
Prof. F. G. R. Fowkes
Cochrane Collaborative Review Group on
Peripheral Vascular Diseases
Public Health Sciences
University of Edinburgh
Teviot Place
Edinburgh EH8 9AG
Tel.:  44-131-650-3220
Fax: 44-131-650-6904
Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/
criticisms facility on the Cochrane Library, or by con-
tacting the group at the above address.
Abstracts
Abstract. Endovascular stents for intermittent
claudication.
P. Bachoo and P. Thorpe
Date of most recent substantive amendment: 24 June
2002
Background
Endovascular stents have been suggested as a means
to improve arterial patency after angioplasty in
patients with intermittent claudication.
Objectives
The null hypothesis to be tested by this review is that
for individuals with claudication the use of an endo-
vascular stent in addition to percutaneous translum-
inal angioplasty does not improve symptoms of
life-style limiting claudication when compared to
percutaneous angioplasty alone.
Search Strategy
We searched the Specialised Register of the Cochrane
Peripheral Vascular Diseases Group, (last searched
October 2002), and the Cochrane Central Register of
Controlled Trials (CENTRAL), (last searched Issue 3,
2002). We also searched MEDLINE and EMBASE (up
to and including January 2001); bibliographies of pub-
lished data, and hand searched the Journal of Vascular
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Interventional Radiology (1990±2001). Enquiries were
made to stent manufacturers for unpublished trial data.
Selection Criteria
Randomised trials comparing angioplasty alone, versus
angioplasty with endovascular stents, in subjects with
intermittent claudication.
Data Collection and Analysis
Both reviewers independently assessed trial quality
and extracted the data. Only published trial data were
used. Effectiveness was measured by pre-defined
primary outcome measures: restenosis/reocclusion
rates and maximum walking distance.
Main Results
Two trials were included with a total sample size of
104 subjects. Both trials included only individuals
with femoro-popliteal disease and compared angio-
plasty and stenting with the Palmaz stent against
angioplasty alone. Although one study showed a
slight statistical advantage in arterial patency after
angioplasty alone, this was not found when the two
studies were combined. No differences in the second-
ary outcomes in either study were detected.
Reviewers' Conclusions
The small number of relevant trials identified,
together with the small sample sizes and methodo-
logical weaknesses, severely limit the usefulness of
this review in guiding practice. Larger multicentre
trials are needed.
Abstract. Once versus twice daily low molecular
weight heparin for the initial treatment of venous
thromboembolism
C. J. van Dongen, M. R. Mac Gillavry and
M. H. Prins
Date of most recent substantive amendment: 17 June
2002
Background
In the initial treatment of venous thromboembolism
(VTE) low molecular weight heparin (LMWH) is
administered once or twice daily. A once daily
treatment regimen is more convenient for the patient
and may optimise home treatment. However, it is not
clear whether a once daily treatment regimen is as safe
and effective as a twice daily treatment regimen.
Objectives
The objective of this review was to compare the effi-
cacy and safety of once daily administration to a twice
daily administration of LMWH.
Search Strategy
Trials were identified through the Specialised Register
of the Cochrane Peripheral Vascular Diseases Group
(last searched May 2001), the Cochrane Controlled
Trials Register (CCTR/CENTRAL) (last searched
Issue 1, 2002), by hand-searching other relevant
journals, by checking cross-references and through
personal communication with experts.
Selection Criteria
Randomised clinical trials in which a once daily treat-
ment regimen with LMWH is compared to a twice
daily regimen in the initial treatment of patients with
venous thromboembolism.
Data Collection and Analysis
Two reviewers assessed trials on criteria for inclusion
and extracted the data independently.
Main Results
Five studies were included with a total of 1508
patients. The pooled data showed a statistically non-
significant difference in recurrent venous thrombo-
embolism between the two treatment regimens (OR
0.82; 0.49±1.39). A comparison of major haemorrhagic
events (OR 0.77; 0.40±1.45) and mortality (OR 1.14;
0.62±2.08) also showed a statistically non-significant
difference between the two treatment regimens.
Reviewers' Conclusions
Once daily treatment with LMWH is as effective and
safe as twice daily treatment with LMWH. However,
the 95% confidence interval implies that there is a
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possibility that the risk of recurrent VTE might be
higher when patients are treated once daily. Hence,
the decision to treat the patient with a once daily
regimen will depend on the evaluated balance
between increased convenience and the potential for
a lower efficacy.
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